Hefei Lifeon Pharmaceutical Co., Ltd. - Laporan Laba Rugi (TTM)

Hefei Lifeon Pharmaceutical Co., Ltd.
CN ˙ SZSE
CN¥ 32.42 ↑0.44 (1.38%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Hefei Lifeon Pharmaceutical Co., Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2023
01-01
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 1,809 1,894 1,991 2,076 2,183 2,273 2,353 2,429 2,503 2,579 2,763 2,618 2,210 1,901 1,423 1,402 1,501 1,518 1,545 1,482
Change (%) 4.70 5.10 4.28 5.15 4.13 3.50 3.23 3.04 3.07 7.10 -5.24 -15.59 -13.98 -25.16 -1.42 7.06 1.14 1.75 -4.11
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 1,210 1,262 1,275 1,293 1,341 1,369 1,418 1,478 1,537 1,619 1,752 1,595 1,272 932 520 436 455 479 509 521
Change (%) 4.25 1.05 1.45 3.70 2.07 3.60 4.23 3.98 5.34 8.20 -8.96 -20.24 -26.72 -44.18 -16.17 4.42 5.27 6.13 2.29
% of Revenue 66.89 66.60 64.04 62.30 61.44 60.22 60.27 60.86 61.42 62.77 63.41 60.92 57.57 49.04 36.58 31.10 30.34 31.57 32.93 35.13
Gross Operating Profit 599 633 716 783 842 904 935 951 966 960 1,011 1,023 938 969 902 966 1,046 1,039 1,036 961
Change (%) 5.60 13.18 9.31 7.55 7.43 3.35 1.70 1.58 -0.55 5.26 1.22 -8.35 3.31 -6.85 7.08 8.26 -0.66 -0.27 -7.25
% of Revenue 33.11 33.40 35.96 37.70 38.56 39.78 39.73 39.14 38.58 37.23 36.59 39.08 42.43 50.96 63.42 68.90 69.66 68.43 67.07 64.87
SG&A 408 433 494 556 609 650 671 675 674 676 700 705 644 663 640 715 780 776 767 696
Change (%) 6.18 13.96 12.66 9.39 6.81 3.29 0.51 -0.19 0.31 3.63 0.60 -8.60 2.95 -3.45 11.73 9.06 -0.50 -1.19 -9.21
% of Revenue 22.56 22.88 24.81 26.80 27.88 28.60 28.54 27.79 26.92 26.20 25.35 26.91 29.14 34.87 44.99 50.99 51.94 51.10 49.63 46.99
R&D 47 43 51 54 52 66 67 68 75 74 73 85 81 85 96 79 79 92 87 107
Change (%) -7.81 18.55 4.36 -2.04 25.47 1.21 1.94 10.90 -2.05 -0.89 16.79 -4.77 4.44 12.96 -17.82 -0.08 16.47 -4.87 22.15
% of Revenue 2.60 2.29 2.58 2.58 2.40 2.90 2.83 2.80 3.01 2.86 2.65 3.26 3.68 4.47 6.75 5.62 5.25 6.04 5.65 7.20
OpEx 1,670 1,751 1,835 1,921 2,021 2,101 2,171 2,231 2,295 2,385 2,544 2,409 2,021 1,695 1,270 1,244 1,331 1,367 1,384 1,345
Change (%) 4.83 4.83 4.66 5.22 3.95 3.34 2.76 2.87 3.91 6.70 -5.30 -16.13 -16.12 -25.09 -2.04 7.02 2.67 1.24 -2.82
% of Revenue 92.30 92.42 92.19 92.52 92.58 92.42 92.28 91.86 91.70 92.45 92.10 92.03 91.45 89.17 89.25 88.69 88.65 89.99 89.54 90.75
Operating Income 139 144 156 155 162 172 182 198 208 195 218 209 189 206 153 159 170 152 162 137
Change (%) 3.06 8.36 -0.21 4.29 6.48 5.43 8.79 5.02 -6.18 12.04 -4.44 -9.36 8.90 -25.71 3.70 7.42 -10.82 6.32 -15.19
% of Revenue 7.70 7.58 7.81 7.48 7.42 7.58 7.72 8.14 8.30 7.55 7.90 7.97 8.55 10.83 10.75 11.31 11.35 10.01 10.46 9.25
Interest Expense -1 -0 -0 -1 -0 -1 -2 -1 -1 -1 -0 -1 -1 -1 -1 -1 -2 -2 -2 -2
Change (%) -62.46 -33.83 327.56 -83.77 1,110.26 33.73 -31.57 6.93 -33.08 -64.68 374.45 -14.67 0.67 9.27 -37.96 92.86 14.64 1.77 27.37
% of Revenue -0.04 -0.01 -0.01 -0.03 -0.01 -0.06 -0.08 -0.05 -0.05 -0.03 -0.01 -0.06 -0.06 -0.07 -0.10 -0.06 -0.11 -0.13 -0.13 -0.17
Net Income 127 135 148 153 161 172 178 187 217 209 228 242 210 227 191 173 174 161 168 173
Change (%) 6.54 9.37 3.30 5.33 7.11 3.16 5.15 16.39 -3.76 9.09 6.11 -13.27 7.90 -15.78 -9.39 0.75 -7.85 4.91 2.92
% of Revenue 7.01 7.13 7.42 7.35 7.37 7.58 7.55 7.69 8.69 8.11 8.26 9.25 9.51 11.93 13.42 12.33 11.61 10.58 10.90 11.70

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista